Bearcats的个人主页 - 老虎社区

Bearcats

Bearcats

暂无个人介绍

IP属地：未知

8关注

0粉丝

0主题

0勋章

2021-06-29

Nice

抱歉，原内容已删除

2021-11-26

Mmmmm[开心]

Microsoft CEO Satya Nadella discloses sale of 839K shares

2021-11-26

$Palantir Technologies Inc.(PLTR)$上上下下上上下... Drop some more so that I can consolidate!!

2021-11-24

$Palantir Technologies Inc.(PLTR)$whats happening? Hmm I thought the earnings were not bad..

2021-06-29

Good luck

2 Robinhood Stocks That Could Crush Dogecoin

2021-04-12

$NIO Inc.(NIO)$Nio oh Nio ..y are u dropping like meiyou?

2021-11-26

Nice!

抱歉，原内容已删除

2021-06-15

Moderna!!

抱歉，原内容已删除

2021-07-02

Wao.. doesn't look good

BUZZ-China's JW falls most in 4 months on shareholder stake sale plan report

2021-06-15

Thanks!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3578368440899680","uuid":"3578368440899680","gmtCreate":1615279346276,"gmtModify":1623757213988,"name":"Bearcats","pinyin":"bearcats","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":877253713,"gmtCreate":1637937949947,"gmtModify":1637937949947,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877253713","repostId":"1182136836","repostType":4,"repost":{"id":"1182136836","kind":"news","pubTimestamp":1637934244,"share":"https://www.laohu8.com/m/news/1182136836?lang=&edition=full","pubTime":"2021-11-26 21:44","market":"us","language":"en","title":"Cardiovascular Systems Recalls Wirion Embolic Protection System","url":"https://stock-news.laohu8.com/highlight/detail?id=1182136836","media":"Benzinga","summary":"Cardiovascular Systems Inc has commenced a voluntary recall of its WIRION Embolic Protection Systems","content":"<p><b>Cardiovascular Systems Inc</b>&nbsp;has&nbsp;commenced a voluntary recall&nbsp;of its WIRION Embolic Protection Systems (WIRION).</p>\n<ul>\n <li>The unused WRN-D6 models of the WIRION device are being recalled due to receiving complaints regarding filter breakage at the time of retrieval.</li>\n <li>The Company stated that the filter breakage might cause device embolism as well as additional intervention.</li>\n <li>All affected healthcare facilities were informed to stop using and return the unused WIRION devices to the Company.</li>\n <li>CSI has also notified the FDA regarding the voluntary recall.</li>\n <li>The Company has received nine filter breakage complaints so far and plans to recall all the devices currently in customer inventory.</li>\n <li>Between 22 March and 15 November, approximately 697 devices were distributed in the US.</li>\n <li>WIRION is a rapid exchange, pre-loaded filter used as an embolic protection system for removing embolic material (thrombus/debris) while performing atherectomy in calcified lesions of the lower extremities.</li>\n <li>In March, CSI&nbsp;acquired a portfolio of peripheral support catheters&nbsp;from&nbsp;<b>WavePoint Medical</b>.</li>\n <li>These catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to aid in lesion crossing and for guidewire exchanges.</li>\n <li>CSI expects to introduce the acquired catheters as its new ViperCross line in the first half of its fiscal year, ending on 30 June 2022.</li>\n <li><b>Price Action:</b>&nbsp;CSII shares closed at $23.72 on Wednesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiovascular Systems Recalls Wirion Embolic Protection System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiovascular Systems Recalls Wirion Embolic Protection System\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/11/24302601/cardiovascular-systems-recalls-wirion-embolic-protection-system><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cardiovascular Systems Inc has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION).\n\nThe unused WRN-D6 models of the WIRION device are being recalled due to receiving ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24302601/cardiovascular-systems-recalls-wirion-embolic-protection-system\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CSII":"Cardiovascular Systems"},"source_url":"https://www.benzinga.com/news/21/11/24302601/cardiovascular-systems-recalls-wirion-embolic-protection-system","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182136836","content_text":"Cardiovascular Systems Inc has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION).\n\nThe unused WRN-D6 models of the WIRION device are being recalled due to receiving complaints regarding filter breakage at the time of retrieval.\nThe Company stated that the filter breakage might cause device embolism as well as additional intervention.\nAll affected healthcare facilities were informed to stop using and return the unused WIRION devices to the Company.\nCSI has also notified the FDA regarding the voluntary recall.\nThe Company has received nine filter breakage complaints so far and plans to recall all the devices currently in customer inventory.\nBetween 22 March and 15 November, approximately 697 devices were distributed in the US.\nWIRION is a rapid exchange, pre-loaded filter used as an embolic protection system for removing embolic material (thrombus/debris) while performing atherectomy in calcified lesions of the lower extremities.\nIn March, CSI acquired a portfolio of peripheral support catheters from WavePoint Medical.\nThese catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to aid in lesion crossing and for guidewire exchanges.\nCSI expects to introduce the acquired catheters as its new ViperCross line in the first half of its fiscal year, ending on 30 June 2022.\nPrice Action: CSII shares closed at $23.72 on Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877259856,"gmtCreate":1637937848720,"gmtModify":1637937848720,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Mmmmm[开心]&nbsp;","listText":"Mmmmm[开心]&nbsp;","text":"Mmmmm[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877259856","repostId":"1112594184","repostType":4,"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877250026,"gmtCreate":1637937790818,"gmtModify":1637937851255,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>上上下下上上下... Drop some more so that I can consolidate!!","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>上上下下上上下... Drop some more so that I can consolidate!!","text":"$Palantir Technologies Inc.(PLTR)$上上下下上上下... Drop some more so that I can consolidate!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877250026","isVote":1,"tweetType":1,"viewCount":783,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875784376,"gmtCreate":1637689903905,"gmtModify":1637689903905,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>whats happening? Hmm I thought the earnings were not bad..","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>whats happening? Hmm I thought the earnings were not bad..","text":"$Palantir Technologies Inc.(PLTR)$whats happening? Hmm I thought the earnings were not bad..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875784376","isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":156547320,"gmtCreate":1625232786260,"gmtModify":1633942284932,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Wao.. doesn't look good&nbsp;","listText":"Wao.. doesn't look good&nbsp;","text":"Wao.. doesn't look good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156547320","repostId":"2147855544","repostType":2,"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159448589,"gmtCreate":1624978061841,"gmtModify":1633946244365,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/159448589","repostId":"2147343850","repostType":4,"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159440294,"gmtCreate":1624977970118,"gmtModify":1633946246588,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Good luck&nbsp;","listText":"Good luck&nbsp;","text":"Good luck","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159440294","repostId":"2146388793","repostType":4,"repost":{"id":"2146388793","kind":"highlight","pubTimestamp":1624959775,"share":"https://www.laohu8.com/m/news/2146388793?lang=&edition=full","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187537917,"gmtCreate":1623758406139,"gmtModify":1634028890286,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Thanks!","listText":"Thanks!","text":"Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187537917","repostId":"1127014300","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187283308,"gmtCreate":1623755359504,"gmtModify":1634028963574,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"Moderna!!","listText":"Moderna!!","text":"Moderna!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187283308","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":342445374,"gmtCreate":1618239165698,"gmtModify":1634294218963,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578368440899680","idStr":"3578368440899680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Nio oh Nio ..y are u dropping like meiyou?","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Nio oh Nio ..y are u dropping like meiyou?","text":"$NIO Inc.(NIO)$Nio oh Nio ..y are u dropping like meiyou?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/342445374","isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":159448589,"gmtCreate":1624978061841,"gmtModify":1633946244365,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/159448589","repostId":"2147343850","repostType":4,"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":877259856,"gmtCreate":1637937848720,"gmtModify":1637937848720,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Mmmmm[开心]&nbsp;","listText":"Mmmmm[开心]&nbsp;","text":"Mmmmm[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877259856","repostId":"1112594184","repostType":4,"repost":{"id":"1112594184","kind":"news","pubTimestamp":1637937334,"share":"https://www.laohu8.com/m/news/1112594184?lang=&edition=full","pubTime":"2021-11-26 22:35","market":"us","language":"en","title":"Microsoft CEO Satya Nadella discloses sale of 839K shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1112594184","media":"seekingalpha","summary":"Microsoft(NASDAQ:MSFT)CEO, Satya Nadella sold ~838.6K between November 22 and November 23.\nShares we","content":"<p>Microsoft(NASDAQ:MSFT)CEO, Satya Nadella sold ~838.6K between&nbsp;November 22 and November 23.</p>\n<p>Shares were sold in a price range of $334.37 and $349.22.</p>\n<p>This brings his total share count to 831K shares.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft CEO Satya Nadella discloses sale of 839K shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft CEO Satya Nadella discloses sale of 839K shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3774587-microsoft-drops-13-as-ceo-satya-nadella-sells-8386k-shares><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Microsoft(NASDAQ:MSFT)CEO, Satya Nadella sold ~838.6K between November 22 and November 23.\nShares were sold in a price range of $334.37 and $349.22.\nThis brings his total share count to 831K shares.</p>\n\n<a href=\"https://seekingalpha.com/news/3774587-microsoft-drops-13-as-ceo-satya-nadella-sells-8386k-shares\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://seekingalpha.com/news/3774587-microsoft-drops-13-as-ceo-satya-nadella-sells-8386k-shares","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112594184","content_text":"Microsoft(NASDAQ:MSFT)CEO, Satya Nadella sold ~838.6K between November 22 and November 23.\nShares were sold in a price range of $334.37 and $349.22.\nThis brings his total share count to 831K shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877250026,"gmtCreate":1637937790818,"gmtModify":1637937851255,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>上上下下上上下... Drop some more so that I can consolidate!!","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>上上下下上上下... Drop some more so that I can consolidate!!","text":"$Palantir Technologies Inc.(PLTR)$上上下下上上下... Drop some more so that I can consolidate!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877250026","isVote":1,"tweetType":1,"viewCount":783,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875784376,"gmtCreate":1637689903905,"gmtModify":1637689903905,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>whats happening? Hmm I thought the earnings were not bad..","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>whats happening? Hmm I thought the earnings were not bad..","text":"$Palantir Technologies Inc.(PLTR)$whats happening? Hmm I thought the earnings were not bad..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875784376","isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":159440294,"gmtCreate":1624977970118,"gmtModify":1633946246588,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Good luck&nbsp;","listText":"Good luck&nbsp;","text":"Good luck","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159440294","repostId":"2146388793","repostType":4,"repost":{"id":"2146388793","kind":"highlight","pubTimestamp":1624959775,"share":"https://www.laohu8.com/m/news/2146388793?lang=&edition=full","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":342445374,"gmtCreate":1618239165698,"gmtModify":1634294218963,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Nio oh Nio ..y are u dropping like meiyou?","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Nio oh Nio ..y are u dropping like meiyou?","text":"$NIO Inc.(NIO)$Nio oh Nio ..y are u dropping like meiyou?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/342445374","isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":877253713,"gmtCreate":1637937949947,"gmtModify":1637937949947,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877253713","repostId":"1182136836","repostType":4,"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":187283308,"gmtCreate":1623755359504,"gmtModify":1634028963574,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Moderna!!","listText":"Moderna!!","text":"Moderna!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187283308","repostId":"1167457915","repostType":4,"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156547320,"gmtCreate":1625232786260,"gmtModify":1633942284932,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Wao.. doesn't look good&nbsp;","listText":"Wao.. doesn't look good&nbsp;","text":"Wao.. doesn't look good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156547320","repostId":"2147855544","repostType":2,"repost":{"id":"2147855544","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624932926,"share":"https://www.laohu8.com/m/news/2147855544?lang=&edition=full","pubTime":"2021-06-29 10:15","market":"hk","language":"en","title":"BUZZ-China's JW falls most in 4 months on shareholder stake sale plan report","url":"https://stock-news.laohu8.com/highlight/detail?id=2147855544","media":"Reuters","summary":"** Shares of Chinese cell therapy developer JW Cayman Therapeutics Co Ltd    fall 10.6% to HK$27.70,","content":"<html><body><p>** Shares of Chinese cell therapy developer JW Cayman Therapeutics Co Ltd    fall 10.6% to HK$27.70, posting their biggest intraday percentage decline since Feb. 22</p><p>   ** Stock hits the lowest since June 18; the second-most actively traded by turnover and the seventh-biggest percentage decliner on the Hong Kong bourse</p><p>   ** WuXi AppTec (Hong Kong) Holding has launched a HK$670 mln ($85 mln) block sale in JW Cayman Therapeutics in a HK$28.50–$29.15/shr range, Refinitiv publication IFR reported</p><p>   ** Range represents a 6%–8.1% discount to the pre-deal close of HK$31 </p><p>   ** Up to 23 mln shares, or 5.7% of the existing capital, are on offer</p><p>   ** Hong Kong's healthcare index    up 0.2%</p><p>   ** The Hang Seng China Enterprises Index    slips 0.3%, and the benchmark index    eases 0.4%</p><p>   ** The stock of the Shangahi-based JW had surged 17.7% this year, as of last close </p><p> (Reporting by Donny Kwok)</p><p>((donny.kwok@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-China's JW falls most in 4 months on shareholder stake sale plan report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-China's JW falls most in 4 months on shareholder stake sale plan report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-29 10:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Shares of Chinese cell therapy developer JW Cayman Therapeutics Co Ltd    fall 10.6% to HK$27.70, posting their biggest intraday percentage decline since Feb. 22</p><p>   ** Stock hits the lowest since June 18; the second-most actively traded by turnover and the seventh-biggest percentage decliner on the Hong Kong bourse</p><p>   ** WuXi AppTec (Hong Kong) Holding has launched a HK$670 mln ($85 mln) block sale in JW Cayman Therapeutics in a HK$28.50–$29.15/shr range, Refinitiv publication IFR reported</p><p>   ** Range represents a 6%–8.1% discount to the pre-deal close of HK$31 </p><p>   ** Up to 23 mln shares, or 5.7% of the existing capital, are on offer</p><p>   ** Hong Kong's healthcare index    up 0.2%</p><p>   ** The Hang Seng China Enterprises Index    slips 0.3%, and the benchmark index    eases 0.4%</p><p>   ** The stock of the Shangahi-based JW had surged 17.7% this year, as of last close </p><p> (Reporting by Donny Kwok)</p><p>((donny.kwok@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02126":"药明巨诺-B"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147855544","content_text":"** Shares of Chinese cell therapy developer JW Cayman Therapeutics Co Ltd    fall 10.6% to HK$27.70, posting their biggest intraday percentage decline since Feb. 22   ** Stock hits the lowest since June 18; the second-most actively traded by turnover and the seventh-biggest percentage decliner on the Hong Kong bourse   ** WuXi AppTec (Hong Kong) Holding has launched a HK$670 mln ($85 mln) block sale in JW Cayman Therapeutics in a HK$28.50–$29.15/shr range, Refinitiv publication IFR reported   ** Range represents a 6%–8.1% discount to the pre-deal close of HK$31    ** Up to 23 mln shares, or 5.7% of the existing capital, are on offer   ** Hong Kong's healthcare index    up 0.2%   ** The Hang Seng China Enterprises Index    slips 0.3%, and the benchmark index    eases 0.4%   ** The stock of the Shangahi-based JW had surged 17.7% this year, as of last close  (Reporting by Donny Kwok)((donny.kwok@thomsonreuters.com))","news_type":1},"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187537917,"gmtCreate":1623758406139,"gmtModify":1634028890286,"author":{"id":"3578368440899680","authorId":"3578368440899680","name":"Bearcats","avatar":"https://static.tigerbbs.com/a5ea7e1d6881483958df90356ea6666e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578368440899680","authorIdStr":"3578368440899680"},"themes":[],"htmlText":"Thanks!","listText":"Thanks!","text":"Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187537917","repostId":"1127014300","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}